10 min listen
Episode 4: Cannabinoid science
FromA view on
ratings:
Length:
9 minutes
Released:
Aug 20, 2020
Format:
Podcast episode
Description
Cannabinoids are emerging as a treatment option for autoimmune and other immune-related diseases thanks to their modifications as synthetic derivatives. Emerald Health Pharmaceuticals has widened the potential application of cannabinoids by designing cannabidiol and cannabigerol derivatives that have a greater effect on the endocannabinoid system and can interact with receptors and pathways from other biosystems. Alain Rolland, COO of EHP, talks about using cannabinoids for unmet medical needs.
Released:
Aug 20, 2020
Format:
Podcast episode
Titles in the series (32)
Episode 3: Mesenchymal stem cells for COVID-19 treatment: Mesoblast CEO Dr. Silviu Itescu speaks to Lonza about the company’s advanced portfolio of anti-inflammatory allogeneic cellular medicines including remestemcel-L, which is currently being evaluated in a U.S. Phase 3 randomized controlled trial for acute ... by A view on